Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma has announced a major strengthening of the patent protection for its product Livatag (doxorubicine Trandrug), currently in phase III clinical trial in primary liver cancer (ReLive trial).
Subscribe to our email newsletter
The European Patent Office has issued a new patent family for Livatag protecting its specific administration scheme. This first delivery should be followed by many others since the patent application is under review in about twenty other territories worldwide (including the US, Asia and Latin America).
Livatag was already patented until 2019 on an international level with a first patent family protecting its composition (doxorubicin encapsulated in nanoparticles). It also benefits from a commercial exclusivity linked to its orphan status in Europe and in the United States, which covers from 7-10 years from the market authorization.
This second patent family significantly strengthens and extends Livatag’s protection as it expands it until 2031, until which period no generic may be commercialized.
BioAlliance Pharma CEO Judith Greciet noted this new patent has not only reinforced but has also strongly extended the protection of Livatag.
"This represents a significant additional potential of revenues for such a product whose estimated level of sales could reach up 800 million euros," Greciet added.